Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRP-HER2 and Pembrolizumab in Advanced HER2+ Breast Cancer
NCT03632941Phase 2Terminated
- Sponsor
- Herbert Lyerly
- Start
- Mar 2019
- Primary completion
- Sep 2023
- Modality
- Vaccines & Immunotherapeutics, Oncolytic Viruses, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing VRP-HER2 Vaccine, Pembrolizumab and VRP-HER2 Vaccine + Pembrolizumab (3 arms). Primary endpoint: Number of Participants With a Positive T Cell Response Based on ELISpot Results at 15 weeks. Started Mar 2019; status: terminated.
02
Drugs
AVX901pembrolizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03632941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03632941.